Ose Immunotherapeutics

Université De Nantes

Institut National De La Sante Et De La Recherche Medicale

Inserm (institut National De La Sante Et De La Recherche Medicale)

Nantes Université

Inserm

Vanessa Gauttier

Nicolas Poirier

Bernard Vanhove

Caroline Mary

Sabrina Pengam

Virginie Thepenier

Elise Chiffoleau

Géraldine Teppaz

Geraldine Teppaz

Marion Drouin

The invention pertains to the field of immunotherapy. The present invention provides specific humanized anti-CLEC-1A antibodies, antigen-binding fragments thereof and mimetics thereof, in particular antibodies. The compounds of the invention are able to specifically binds to CLEC-1A receptor and antagonize the binding of CLEC-1A to its endogenous ligand(s). The compounds of the invention can be used to treat deleterious conditions.

Humanized anti-CLEC-1A antibodies and antigen-binding fragments thereof

The invention pertains to the field of immunotherapy. The present invention provides new uses of anti-SIRPg antibodies for the treatment and/or the prevention of autoimmune disorders or diseases.

Uses of anti-SIRPg antibodies

The present invention provides new anti-SIRPa antibodies able to specifically antagonize the interaction between SIRPa and CD47, without affecting the interaction between SIRPg and CD47, and their uses.

Anti-SIRPa antibodies and their therapeutic applications

The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.

Method of promoting a t-cell response or treating cancer by administering an antagonist to human c-type lectin-like receptor-1 (CLEC-1)

The invention is in the field of immunotherapy. The present invention provides antibodies useful in therapeutic and diagnostic applications targeting human SIRPa, said antibodies enhancing the cross-presentation of antigens to T cells. The invention also provides antibodies against specific isoforms of SIRP a and able to disrupt the interaction between those isoforms of SIRP a and human CD47 for use in treating or preventing a disease, or diagnostic applications, and methods for producing and/or selecting anti-human SIRPa antibodies that bind with different affinities to various isoforms of human SIRP members.

Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies

Methods for promoting t cells response by administering an antagonist of human c-type lectin-like receptor 1 (CLEC-1)

Growing community of inventors

Rezé, France

Vanessa Gauttier